Melphalan
Melphalan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
14 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Memorial Sloan Kettering Cancer Center
- Masonic Cancer Center, University of Minnesota
- Delcath Systems Inc.
- University of Wisconsin, Madison
- Uppsala University
- City of Hope Medical Center
- University of California, Irvine
- SWOG Cancer Research Network
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Czechia、德国、意大利、荷兰、Serbia、西班牙、Turkey (Türkiye)、英国、瑞典、中国、加拿大
正在招募患者的 Melphalan 研究
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
II 期招募中美国NCT02605421Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
II 期招募中美国Czechia德国意大利NCT06607458Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
I 期招募中美国NCT02508038Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
不适用招募中瑞典NCT06245629Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
I 期招募中美国NCT06996119Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
II 期招募中美国NCT06028828Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
III 期招募中美国NCT06022939Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
II 期招募中美国NCT04370301The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
I 期 / II 期招募中美国NCT05436418Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
II 期招募中美国NCT01962415Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
II 期招募中美国NCT07276386Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
III 期招募中中国NCT07396480Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
I 期 / II 期招募中CzechiaNCT07532824Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
I 期 / II 期招募中美国NCT07281924MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390Transplantation After Complete Response In Patients With T-cell Lymphoma
不适用招募中法国NCT05444712Helical Tomotherapy in Multiple Myeloma
不适用招募中中国NCT05970198Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
II 期招募中美国NCT06207799225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
I 期招募中美国NCT06287944Personalized NK Cell Therapy in CBT
II 期招募中美国NCT02727803Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
II 期招募中中国NCT07400328A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
不适用招募中中国NCT06879847TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
I 期招募中美国NCT07052370Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
II 期招募中美国NCT07284641
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。